 | • レポートコード：MRC2Q12-18846 • 出版社/出版日：QYResearch / 2022年12月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、126ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥744,800 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,489,600 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、降圧剤のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 降圧剤のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 降圧剤の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 降圧剤のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの降圧剤の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の降圧剤の売上および2028年までの予測に焦点を当てています。 降圧剤のグローバル主要企業には、Baxter International、Pfizer、Sandoz、Teva Pharmaceuticals、Bayer、Johnson & Johnson、Sun Pharmaceutical Industries、Merck、AstraZeneca、Daiichi Sankyo、Takeda、Actelion、Viatris、United Therapeutics、Lupin Limited、Hikma Pharmaceuticals、Aurobindo Pharma、Camber Pharmaceutical、Major Pharmaceuticals、Glenmark Pharmaceuticals、Zydus Pharmaceuticals、Amneal Pharmaceuticals、Endo International、Unichem Laboratories、Huahai Pharmaceutical、Shijiazhuang Pharma Group、Shanghai Shyndec Pharmaceuticalなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 降圧剤市場は、タイプとアプリケーションによって区分されます。世界の降圧剤市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 サイアザイド利尿薬、カルシウムチャネル遮断薬（CCB）、ACE阻害薬、アンジオテンシンII受容体拮抗薬（ARB） 【アプリケーション別セグメント】 子供、大人 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 降圧剤製品概要 - タイプ別市場（サイアザイド利尿薬、カルシウムチャネル遮断薬（CCB）、ACE阻害薬、アンジオテンシンII受容体拮抗薬（ARB）） - アプリケーション別市場（子供、大人） - 調査の目的 ・エグゼクティブサマリー - 世界の降圧剤販売量予測2017-2028 - 世界の降圧剤売上予測2017-2028 - 降圧剤の地域別販売量 - 降圧剤の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別降圧剤販売量 - 主要メーカー別降圧剤売上 - 主要メーカー別降圧剤価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（サイアザイド利尿薬、カルシウムチャネル遮断薬（CCB）、ACE阻害薬、アンジオテンシンII受容体拮抗薬（ARB）） - 降圧剤のタイプ別販売量 - 降圧剤のタイプ別売上 - 降圧剤のタイプ別価格 ・アプリケーション別市場規模（子供、大人） - 降圧剤のアプリケーション別販売量 - 降圧剤のアプリケーション別売上 - 降圧剤のアプリケーション別価格 ・北米市場 - 北米の降圧剤市場規模（タイプ別、アプリケーション別） - 主要国別の降圧剤市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの降圧剤市場規模（タイプ別、アプリケーション別） - 主要国別の降圧剤市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の降圧剤市場規模（タイプ別、アプリケーション別） - 主要国別の降圧剤市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の降圧剤市場規模（タイプ別、アプリケーション別） - 主要国別の降圧剤市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの降圧剤市場規模（タイプ別、アプリケーション別） - 主要国別の降圧剤市場規模（トルコ、サウジアラビア） ・企業情報 Baxter International、Pfizer、Sandoz、Teva Pharmaceuticals、Bayer、Johnson & Johnson、Sun Pharmaceutical Industries、Merck、AstraZeneca、Daiichi Sankyo、Takeda、Actelion、Viatris、United Therapeutics、Lupin Limited、Hikma Pharmaceuticals、Aurobindo Pharma、Camber Pharmaceutical、Major Pharmaceuticals、Glenmark Pharmaceuticals、Zydus Pharmaceuticals、Amneal Pharmaceuticals、Endo International、Unichem Laboratories、Huahai Pharmaceutical、Shijiazhuang Pharma Group、Shanghai Shyndec Pharmaceutical ・産業チェーン及び販売チャネル分析 - 降圧剤の産業チェーン分析 - 降圧剤の原材料 - 降圧剤の生産プロセス - 降圧剤の販売及びマーケティング - 降圧剤の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 降圧剤の産業動向 - 降圧剤のマーケットドライバー - 降圧剤の課題 - 降圧剤の阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Antihypertensive Agents estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Antihypertensive Agents is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Antihypertensive Agents is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Antihypertensive Agents is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Antihypertensive Agents include Baxter International, Pfizer, Sandoz, Teva Pharmaceuticals, Bayer, Johnson & Johnson, Sun Pharmaceutical Industries, Merck and AstraZeneca, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Antihypertensive Agents companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Antihypertensive Agents market. Further, it explains the major drivers and regional dynamics of the global Antihypertensive Agents market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Baxter International
Pfizer
Sandoz
Teva Pharmaceuticals
Bayer
Johnson & Johnson
Sun Pharmaceutical Industries
Merck
AstraZeneca
Daiichi Sankyo
Takeda
Actelion
Viatris
United Therapeutics
Lupin Limited
Hikma Pharmaceuticals
Aurobindo Pharma
Camber Pharmaceutical
Major Pharmaceuticals
Glenmark Pharmaceuticals
Zydus Pharmaceuticals
Amneal Pharmaceuticals
Endo International
Unichem Laboratories
Huahai Pharmaceutical
Shijiazhuang Pharma Group
Shanghai Shyndec Pharmaceutical
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Antihypertensive Agents Segment by Type
Thiazide Diuretics
Calcium Channel Blockers (CCB)
ACE Inhibitors
Angiotensin II Receptor Antagonists (ARBs)
Antihypertensive Agents Segment by Application
Children
Adult
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Antihypertensive Agents market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Antihypertensive Agents market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Antihypertensive Agents, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Antihypertensive Agents, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Antihypertensive Agents revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Antihypertensive Agents market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Antihypertensive Agents revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Baxter International, Pfizer, Sandoz, Teva Pharmaceuticals, Bayer, Johnson & Johnson, Sun Pharmaceutical Industries, Merck and AstraZeneca, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Antihypertensive Agents in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antihypertensive Agents companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antihypertensive Agents revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antihypertensive Agents Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Thiazide Diuretics
1.2.3 Calcium Channel Blockers (CCB)
1.2.4 ACE Inhibitors
1.2.5 Angiotensin II Receptor Antagonists (ARBs)
1.3 Market by Application
1.3.1 Global Antihypertensive Agents Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Children
1.3.3 Adult
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Antihypertensive Agents Market Perspective (2017-2028)
2.2 Antihypertensive Agents Growth Trends by Region
2.2.1 Antihypertensive Agents Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Antihypertensive Agents Historic Market Size by Region (2017-2022)
2.2.3 Antihypertensive Agents Forecasted Market Size by Region (2023-2028)
2.3 Antihypertensive Agents Market Dynamics
2.3.1 Antihypertensive Agents Industry Trends
2.3.2 Antihypertensive Agents Market Drivers
2.3.3 Antihypertensive Agents Market Challenges
2.3.4 Antihypertensive Agents Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antihypertensive Agents Players by Revenue
3.1.1 Global Top Antihypertensive Agents Players by Revenue (2017-2022)
3.1.2 Global Antihypertensive Agents Revenue Market Share by Players (2017-2022)
3.2 Global Antihypertensive Agents Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Antihypertensive Agents Revenue
3.4 Global Antihypertensive Agents Market Concentration Ratio
3.4.1 Global Antihypertensive Agents Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antihypertensive Agents Revenue in 2021
3.5 Antihypertensive Agents Key Players Head office and Area Served
3.6 Key Players Antihypertensive Agents Product Solution and Service
3.7 Date of Enter into Antihypertensive Agents Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Antihypertensive Agents Breakdown Data by Type
4.1 Global Antihypertensive Agents Historic Market Size by Type (2017-2022)
4.2 Global Antihypertensive Agents Forecasted Market Size by Type (2023-2028)
5 Antihypertensive Agents Breakdown Data by Application
5.1 Global Antihypertensive Agents Historic Market Size by Application (2017-2022)
5.2 Global Antihypertensive Agents Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Antihypertensive Agents Market Size (2017-2028)
6.2 North America Antihypertensive Agents Market Size by Type
6.2.1 North America Antihypertensive Agents Market Size by Type (2017-2022)
6.2.2 North America Antihypertensive Agents Market Size by Type (2023-2028)
6.2.3 North America Antihypertensive Agents Market Share by Type (2017-2028)
6.3 North America Antihypertensive Agents Market Size by Application
6.3.1 North America Antihypertensive Agents Market Size by Application (2017-2022)
6.3.2 North America Antihypertensive Agents Market Size by Application (2023-2028)
6.3.3 North America Antihypertensive Agents Market Share by Application (2017-2028)
6.4 North America Antihypertensive Agents Market Size by Country
6.4.1 North America Antihypertensive Agents Market Size by Country (2017-2022)
6.4.2 North America Antihypertensive Agents Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Antihypertensive Agents Market Size (2017-2028)
7.2 Europe Antihypertensive Agents Market Size by Type
7.2.1 Europe Antihypertensive Agents Market Size by Type (2017-2022)
7.2.2 Europe Antihypertensive Agents Market Size by Type (2023-2028)
7.2.3 Europe Antihypertensive Agents Market Share by Type (2017-2028)
7.3 Europe Antihypertensive Agents Market Size by Application
7.3.1 Europe Antihypertensive Agents Market Size by Application (2017-2022)
7.3.2 Europe Antihypertensive Agents Market Size by Application (2023-2028)
7.3.3 Europe Antihypertensive Agents Market Share by Application (2017-2028)
7.4 Europe Antihypertensive Agents Market Size by Country
7.4.1 Europe Antihypertensive Agents Market Size by Country (2017-2022)
7.4.2 Europe Antihypertensive Agents Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antihypertensive Agents Market Size (2017-2028)
8.2 Asia-Pacific Antihypertensive Agents Market Size by Type
8.2.1 Asia-Pacific Antihypertensive Agents Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Antihypertensive Agents Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Antihypertensive Agents Market Share by Type (2017-2028)
8.3 Asia-Pacific Antihypertensive Agents Market Size by Application
8.3.1 Asia-Pacific Antihypertensive Agents Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Antihypertensive Agents Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Antihypertensive Agents Market Share by Application (2017-2028)
8.4 Asia-Pacific Antihypertensive Agents Market Size by Region
8.4.1 Asia-Pacific Antihypertensive Agents Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Antihypertensive Agents Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Antihypertensive Agents Market Size (2017-2028)
9.2 Latin America Antihypertensive Agents Market Size by Type
9.2.1 Latin America Antihypertensive Agents Market Size by Type (2017-2022)
9.2.2 Latin America Antihypertensive Agents Market Size by Type (2023-2028)
9.2.3 Latin America Antihypertensive Agents Market Share by Type (2017-2028)
9.3 Latin America Antihypertensive Agents Market Size by Application
9.3.1 Latin America Antihypertensive Agents Market Size by Application (2017-2022)
9.3.2 Latin America Antihypertensive Agents Market Size by Application (2023-2028)
9.3.3 Latin America Antihypertensive Agents Market Share by Application (2017-2028)
9.4 Latin America Antihypertensive Agents Market Size by Country
9.4.1 Latin America Antihypertensive Agents Market Size by Country (2017-2022)
9.4.2 Latin America Antihypertensive Agents Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antihypertensive Agents Market Size (2017-2028)
10.2 Middle East & Africa Antihypertensive Agents Market Size by Type
10.2.1 Middle East & Africa Antihypertensive Agents Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Antihypertensive Agents Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Antihypertensive Agents Market Share by Type (2017-2028)
10.3 Middle East & Africa Antihypertensive Agents Market Size by Application
10.3.1 Middle East & Africa Antihypertensive Agents Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Antihypertensive Agents Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Antihypertensive Agents Market Share by Application (2017-2028)
10.4 Middle East & Africa Antihypertensive Agents Market Size by Country
10.4.1 Middle East & Africa Antihypertensive Agents Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Antihypertensive Agents Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Baxter International
11.1.1 Baxter International Company Details
11.1.2 Baxter International Business Overview
11.1.3 Baxter International Antihypertensive Agents Introduction
11.1.4 Baxter International Revenue in Antihypertensive Agents Business (2017-2022)
11.1.5 Baxter International Recent Developments
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Antihypertensive Agents Introduction
11.2.4 Pfizer Revenue in Antihypertensive Agents Business (2017-2022)
11.2.5 Pfizer Recent Developments
11.3 Sandoz
11.3.1 Sandoz Company Details
11.3.2 Sandoz Business Overview
11.3.3 Sandoz Antihypertensive Agents Introduction
11.3.4 Sandoz Revenue in Antihypertensive Agents Business (2017-2022)
11.3.5 Sandoz Recent Developments
11.4 Teva Pharmaceuticals
11.4.1 Teva Pharmaceuticals Company Details
11.4.2 Teva Pharmaceuticals Business Overview
11.4.3 Teva Pharmaceuticals Antihypertensive Agents Introduction
11.4.4 Teva Pharmaceuticals Revenue in Antihypertensive Agents Business (2017-2022)
11.4.5 Teva Pharmaceuticals Recent Developments
11.5 Bayer
11.5.1 Bayer Company Details
11.5.2 Bayer Business Overview
11.5.3 Bayer Antihypertensive Agents Introduction
11.5.4 Bayer Revenue in Antihypertensive Agents Business (2017-2022)
11.5.5 Bayer Recent Developments
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Company Details
11.6.2 Johnson & Johnson Business Overview
11.6.3 Johnson & Johnson Antihypertensive Agents Introduction
11.6.4 Johnson & Johnson Revenue in Antihypertensive Agents Business (2017-2022)
11.6.5 Johnson & Johnson Recent Developments
11.7 Sun Pharmaceutical Industries
11.7.1 Sun Pharmaceutical Industries Company Details
11.7.2 Sun Pharmaceutical Industries Business Overview
11.7.3 Sun Pharmaceutical Industries Antihypertensive Agents Introduction
11.7.4 Sun Pharmaceutical Industries Revenue in Antihypertensive Agents Business (2017-2022)
11.7.5 Sun Pharmaceutical Industries Recent Developments
11.8 Merck
11.8.1 Merck Company Details
11.8.2 Merck Business Overview
11.8.3 Merck Antihypertensive Agents Introduction
11.8.4 Merck Revenue in Antihypertensive Agents Business (2017-2022)
11.8.5 Merck Recent Developments
11.9 AstraZeneca
11.9.1 AstraZeneca Company Details
11.9.2 AstraZeneca Business Overview
11.9.3 AstraZeneca Antihypertensive Agents Introduction
11.9.4 AstraZeneca Revenue in Antihypertensive Agents Business (2017-2022)
11.9.5 AstraZeneca Recent Developments
11.10 Daiichi Sankyo
11.10.1 Daiichi Sankyo Company Details
11.10.2 Daiichi Sankyo Business Overview
11.10.3 Daiichi Sankyo Antihypertensive Agents Introduction
11.10.4 Daiichi Sankyo Revenue in Antihypertensive Agents Business (2017-2022)
11.10.5 Daiichi Sankyo Recent Developments
11.11 Takeda
11.11.1 Takeda Company Details
11.11.2 Takeda Business Overview
11.11.3 Takeda Antihypertensive Agents Introduction
11.11.4 Takeda Revenue in Antihypertensive Agents Business (2017-2022)
11.11.5 Takeda Recent Developments
11.12 Actelion
11.12.1 Actelion Company Details
11.12.2 Actelion Business Overview
11.12.3 Actelion Antihypertensive Agents Introduction
11.12.4 Actelion Revenue in Antihypertensive Agents Business (2017-2022)
11.12.5 Actelion Recent Developments
11.13 Viatris
11.13.1 Viatris Company Details
11.13.2 Viatris Business Overview
11.13.3 Viatris Antihypertensive Agents Introduction
11.13.4 Viatris Revenue in Antihypertensive Agents Business (2017-2022)
11.13.5 Viatris Recent Developments
11.14 United Therapeutics
11.14.1 United Therapeutics Company Details
11.14.2 United Therapeutics Business Overview
11.14.3 United Therapeutics Antihypertensive Agents Introduction
11.14.4 United Therapeutics Revenue in Antihypertensive Agents Business (2017-2022)
11.14.5 United Therapeutics Recent Developments
11.15 Lupin Limited
11.15.1 Lupin Limited Company Details
11.15.2 Lupin Limited Business Overview
11.15.3 Lupin Limited Antihypertensive Agents Introduction
11.15.4 Lupin Limited Revenue in Antihypertensive Agents Business (2017-2022)
11.15.5 Lupin Limited Recent Developments
11.16 Hikma Pharmaceuticals
11.16.1 Hikma Pharmaceuticals Company Details
11.16.2 Hikma Pharmaceuticals Business Overview
11.16.3 Hikma Pharmaceuticals Antihypertensive Agents Introduction
11.16.4 Hikma Pharmaceuticals Revenue in Antihypertensive Agents Business (2017-2022)
11.16.5 Hikma Pharmaceuticals Recent Developments
11.17 Aurobindo Pharma
11.17.1 Aurobindo Pharma Company Details
11.17.2 Aurobindo Pharma Business Overview
11.17.3 Aurobindo Pharma Antihypertensive Agents Introduction
11.17.4 Aurobindo Pharma Revenue in Antihypertensive Agents Business (2017-2022)
11.17.5 Aurobindo Pharma Recent Developments
11.18 Camber Pharmaceutical
11.18.1 Camber Pharmaceutical Company Details
11.18.2 Camber Pharmaceutical Business Overview
11.18.3 Camber Pharmaceutical Antihypertensive Agents Introduction
11.18.4 Camber Pharmaceutical Revenue in Antihypertensive Agents Business (2017-2022)
11.18.5 Camber Pharmaceutical Recent Developments
11.19 Major Pharmaceuticals
11.19.1 Major Pharmaceuticals Company Details
11.19.2 Major Pharmaceuticals Business Overview
11.19.3 Major Pharmaceuticals Antihypertensive Agents Introduction
11.19.4 Major Pharmaceuticals Revenue in Antihypertensive Agents Business (2017-2022)
11.19.5 Major Pharmaceuticals Recent Developments
11.20 Glenmark Pharmaceuticals
11.20.1 Glenmark Pharmaceuticals Company Details
11.20.2 Glenmark Pharmaceuticals Business Overview
11.20.3 Glenmark Pharmaceuticals Antihypertensive Agents Introduction
11.20.4 Glenmark Pharmaceuticals Revenue in Antihypertensive Agents Business (2017-2022)
11.20.5 Glenmark Pharmaceuticals Recent Developments
11.21 Zydus Pharmaceuticals
11.21.1 Zydus Pharmaceuticals Company Details
11.21.2 Zydus Pharmaceuticals Business Overview
11.21.3 Zydus Pharmaceuticals Antihypertensive Agents Introduction
11.21.4 Zydus Pharmaceuticals Revenue in Antihypertensive Agents Business (2017-2022)
11.21.5 Zydus Pharmaceuticals Recent Developments
11.22 Amneal Pharmaceuticals
11.22.1 Amneal Pharmaceuticals Company Details
11.22.2 Amneal Pharmaceuticals Business Overview
11.22.3 Amneal Pharmaceuticals Antihypertensive Agents Introduction
11.22.4 Amneal Pharmaceuticals Revenue in Antihypertensive Agents Business (2017-2022)
11.22.5 Amneal Pharmaceuticals Recent Developments
11.23 Endo International
11.23.1 Endo International Company Details
11.23.2 Endo International Business Overview
11.23.3 Endo International Antihypertensive Agents Introduction
11.23.4 Endo International Revenue in Antihypertensive Agents Business (2017-2022)
11.23.5 Endo International Recent Developments
11.24 Unichem Laboratories
11.24.1 Unichem Laboratories Company Details
11.24.2 Unichem Laboratories Business Overview
11.24.3 Unichem Laboratories Antihypertensive Agents Introduction
11.24.4 Unichem Laboratories Revenue in Antihypertensive Agents Business (2017-2022)
11.24.5 Unichem Laboratories Recent Developments
11.25 Huahai Pharmaceutical
11.25.1 Huahai Pharmaceutical Company Details
11.25.2 Huahai Pharmaceutical Business Overview
11.25.3 Huahai Pharmaceutical Antihypertensive Agents Introduction
11.25.4 Huahai Pharmaceutical Revenue in Antihypertensive Agents Business (2017-2022)
11.25.5 Huahai Pharmaceutical Recent Developments
11.26 Shijiazhuang Pharma Group
11.26.1 Shijiazhuang Pharma Group Company Details
11.26.2 Shijiazhuang Pharma Group Business Overview
11.26.3 Shijiazhuang Pharma Group Antihypertensive Agents Introduction
11.26.4 Shijiazhuang Pharma Group Revenue in Antihypertensive Agents Business (2017-2022)
11.26.5 Shijiazhuang Pharma Group Recent Developments
11.27 Shanghai Shyndec Pharmaceutical
11.27.1 Shanghai Shyndec Pharmaceutical Company Details
11.27.2 Shanghai Shyndec Pharmaceutical Business Overview
11.27.3 Shanghai Shyndec Pharmaceutical Antihypertensive Agents Introduction
11.27.4 Shanghai Shyndec Pharmaceutical Revenue in Antihypertensive Agents Business (2017-2022)
11.27.5 Shanghai Shyndec Pharmaceutical Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
| 【降圧剤について】 ※降圧剤（こうあつざい）とは、高血圧の治療に用いられる医薬品のことを指します。高血圧は、心臓や血管に多くの負担をかけるため、放置すると心疾患や脳卒中、腎疾患などのリスクが高まります。降圧剤は、血圧を正常値に保つことで、これらの合併症の予防を目的としています。 降圧剤の特徴としては、主に血圧を下げるメカニズムが異なることが挙げられます。一般的には、心拍出量を減少させたり、血管を拡張させて末梢抵抗を低下させたりすることで血圧を低下させます。これにより、心臓の負担を軽減し、血圧を安定させることができます。 降圧剤は大きく分けていくつかの種類に分類されます。代表的なものとしては、以下のクラスが存在します。 1. 利尿薬（りにょうやく）: このタイプの薬剤は、腎臓からの水分と塩分の排出を促進し、血液の量を減少させることによって血圧を下げます。一般的には、サイアザイド系利尿薬やループ利尿薬が使用されます。 2. ACE阻害剤（エースそがいざい）: アンジオテンシン変換酵素（ACE）を阻害することで、血管収縮を引き起こすホルモンの生成を抑制し、血圧を低下させます。例として、エナラプリルやリシノプリルがあります。 3. ARB（アンジオテンシンII受容体拮抗薬）: アンジオテンシンIIの受容体をブロックすることで、血管を拡張させ、血圧を下げる効果があります。ロサルタンやカンデサルタンが代表的な薬剤です。 4. β遮断薬（ベータしゃだんやく）: 心拍数を減少させ、心筋の収縮力を抑えることで血圧を低下させます。アテノロールやメトプロロールが多く使われています。 5. カルシウムチャネルブロッカー: 血管平滑筋のカルシウムチャネルをブロックすることで、血管を拡張させ、血圧を下げる薬剤です。ジヒドロピリジン系やフェニルアルキルアミン系が含まれます。 降圧剤の用途は多岐にわたりますが、主な目的は高血圧の管理です。高血圧は多くの場合、生活習慣病とも関連しているため、降圧剤の使用が生活改善指導と併用されることが一般的です。また、心不全や狭心症、慢性腎不全などの疾患に対しても、降圧剤は有用とされています。 降圧剤の効果には個人差があり、同じ薬剤でも効果が異なることがあります。そのため、医師は患者の状態や合併症、生活スタイルに応じて最適な薬剤や用量を選定します。また、副作用のリスクも考慮されるため、必要に応じて他の薬剤との併用、または治療法の見直しが行われることがあります。 最近では、降圧剤の新たな治療法や関連技術の開発も進んでいます。例えば、再生医療や遺伝子治療技術を利用した治療法が研究されています。また、モニタリング技術の進化により、患者の血圧をリアルタイムで管理できるデバイスやアプリが開発され、医師や患者の治療の助けとなっています。 降圧剤は、高血圧の治療において極めて重要な役割を果たしており、多くの患者に恩恵をもたらしています。ただし、薬剤の効果や副作用に関しては個々の患者において異なるため、適切な使用と医療機関でのフォローアップが重要です。自分に合った治療法を見つけるためには、医師との密なコミュニケーションと定期的な検査が必要不可欠です。 降圧剤は生活習慣の改善と併用して使用されることが多く、食事の見直しや適度な運動、ストレスの管理なども重要な要素です。特に、塩分の摂取制限や野菜中心の食事、禁煙などは、降圧効果を高めるために効果的です。降圧剤を使用しながら生活改善を行うことで、より良好な血圧管理が実現できるでしょう。 今後も降圧剤に関する研究は続き、新しい治療法や薬剤の開発が期待されています。高血圧は世界中での健康問題として取り上げられており、その管理は医療の重要な課題です。降圧剤は、その一助となる therapeutics として、ますます重要性を増していくことでしょう。 |